Latest Conference Articles

In another segment of her interview with HCPLive, Graber explored some of the latest treatment developments for acne and rosacea covered in her 2023 Winter Clinical Miami presentation.

In an HCPLive interview on her Winter Clinical Miami presentation, Graber describes several new developments in the dermatology space regarding acne and rosacea treatments.

In another segment of his interview, Mark Lebwohl, MD, discussed the various ways to address different psoriasis patients depending on their backgrounds with obesity, cancer, and psoriatic arthritis.

Philip Mease, MD, discusses other factors, besides drug inefficacy, that may impact pain in patients with rheumatic and autoimmune conditions.

In his recent interview, Mark Lebwohl, MD, spoke about his Winter Clinical Miami presentation titled ‘Psoriasis: Which Drug for Which Patient?’ and some of its highlights.

Anisha Dua, MD, MPH, emphasized the looming workforce shortage, the challenges of attracting medical students to this field, and how practices changed during the COVID-19 pandemic.

Anisha Dua, MD, MPH, defines IgG4 and explains why IgG4-related disease is often difficult to diagnose, in part because it regularly affects a variety of organ systems.

The connection between different ADHD subtypes and mood disorders has not been fully explored.

Singh presented during the recent APSARD conference. onthe topic of ADHD and bipolar disorder.

The FDA has approved several biologics in recent years for the treatment of patients with inflammatory bowel disease.

The FDA has set a PDUFA date for daprodustat for February 1 for adult patients with chronic kidney disease.

Crosbie presented results from a small pilot study testing a video game platform for patients with executive function deficits during the annual APSARD meeting.

Falloon said IBD-associated peripheral arthritis is common, but not well understood.

There is not much data available on the interaction between Paxlovid and tacrolimus.

Dose de-escalation of tofacitinib resulted in less hospitalizations for patients with ulcerative colitis.

The potential for personalized medicine in inflammatory bowel disease might. be realized in the next few years.

Upadacitinib was not approved by the FDA until 2022 for patients with ulcerative colitis.

A discussion with Henry Lim, MD, during an interview segment in which he described photoprotection measures for various skin phenotypes and his outlook on future research.

The 12-24 session counseling program also resulted in improvements in sleep quality, fatigue level, and stress levels for patients with inflammatory bowel disease.

The majority of patients who achieved persistence at the 12 month mark were also corticosteroid free.

The product is a combination of herbal compounds curcumin and QingDai called CurQD.

Microscopic inflammation can be an important indicator of disease activity in patients with ulcerative colitis.

An interview segment on HCPLive with James Del Rosso, DO, in which he explores key highlights from his presentation at the 2023 Winter Clinical conference.

An HCPLive interview with Henry Lim, MD, during which he describes the differing needs of various skin types and the differences in sunscreen regulations.

An interview segment with Henry Lim, MD, on his presentation from Winter Clinical regarding different photoprotection measures for different phenotypes.

In a segment of his HCPLive interview regarding his Winter Clinical presentation, James Del Rosso, DO, highlighted several points about acne and rosacea treatment.

This segment of Raj Chovatiya’s interview with HCPLive, a discussion was conducted regarding facts about abrocitinib for atopic dermatitis treatment.

During an HCPLive interview on his presentation at Winter Clinical, Raj Chovatiya discussed the use of abrocitinib on atopic dermatitis patients.

In a Q&A interview with Glynis Ablon, the dermatologist described highlights from her recent Winter Clinical presentation on new devices for clinical practice.

"The challenge right now is that we have no therapies in the emergency department to treat acute pain, outside of pain medications and IV opioids," Dr. Claudia Morris says in an interview.